Status:

COMPLETED

Adjunctive, Low-dose tPA in Primary PCI for STEMI

Lead Sponsor:

Population Health Research Institute

Collaborating Sponsors:

Heart and Stroke Foundation of Canada

Conditions:

Myocardial Infarction

Percutaneous Coronary Intervention

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

STRIVE will evaluate the use of adjunctive, low-dose intracoronary tissue plasminogen activator during primary percutaneous coronary intervention (PCI) for patients with ST elevation myocardial infarc...

Detailed Description

STRIVE is a prospective, 3-arm, parallel group, blinded, randomized controlled trial evaluating the efficacy of a novel approach to prevent and treat microvascular obstruction thereby reducing major c...

Eligibility Criteria

Inclusion

  • Patients with STEMI undergoing primary PCI and,
  • ECG changes indicating large territory STEMI (defined as ≥2mm ST-segment elevation in 2 contiguous anterior precordial leads; or ≥2mm ST-segment elevation in 2 inferior leads coupled with ST-segment depression in 2 contiguous anterior leads for a total ST-segment deviation of ≥8mm) and,
  • Randomization within 6 to 12 hours of symptom onset and,
  • Large thrombus burden with angiographic TIMI Thrombus Grade ≥3 after guidewire crossing.

Exclusion

  • Active internal bleeding or high risk of bleeding or any prior intracranial bleeding.
  • Any other absolute or relative contraindication to fibrinolytic therapy.
  • Administration of a fibrinolytic ≤24hrs prior to randomization.
  • Cardiogenic shock on presentation.
  • Left bundle branch block (excluded because the ECG cannot be evaluated for ST segment resolution, an outcome of the study).
  • Planned upfront use of a glycoprotein IIb/IIIa inhibitor.
  • Any medical, geographic, or social factor making study participation impractical or precluding 1 month follow-up.

Key Trial Info

Start Date :

April 1 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 12 2025

Estimated Enrollment :

210 Patients enrolled

Trial Details

Trial ID

NCT03335839

Start Date

April 1 2018

End Date

February 12 2025

Last Update

September 26 2025

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

University of Calgary - Foothills Medical Centre

Calgary, Alberta, Canada, T2N 4Z6

2

University of Alberta - Mazankowski Alberta Heart Insitute

Edmonton, Alberta, Canada, T6G 2B7

3

Hamilton General Hospital

Hamilton, Ontario, Canada, L8L2X2